Skip to content

Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative

Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative to Improve Diabetes Care, Its Health Outcomes and Economic Costs

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00160017
Enrollment
1861
Registered
2005-09-12
Start date
2005-01-31
Completion date
2008-03-31
Last updated
2015-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Keywords

Quality assurance health care, Diabetes, Breakthrough collaborative (IHI), Evaluation

Brief summary

The study tests whether implementing professional evidence-based guidelines and best practices for diabetes care -through participation of multidisciplinary teams in a Breakthrough collaborative- results in an improvement of diabetes care, its health outcomes and economic costs. Determinants of success are studied. Data on diabetes will also be used to better understand Breakthrough as an implementation or improvement method.

Detailed description

Diabetes mellitus as a chronic disease is a major and growing health care problem. Studies on the prevention of severe complications provide evidence for the necessity of tight control. Different interventions and models to achieve strict control and reduce diabetes related risks of complications are available. These are, however, not implemented in daily practice. Our study focuses on this implementation problem: it tests whether implementing professional evidence-based guidelines and best practices -through participation of multidisciplinary teams in the Breakthrough collaborative- results in an improvement of diabetes care, its health outcomes and economic costs. Data on diabetes will also be used to explore and better understand the Breakthrough model as an implementation method. Only uncontrolled observational studies have, so far, described the outcomes of Breakthrough collaboratives. They also describe significant differences between teams in specific improvements made in patient care and organisational performance, resulting in different implementation and medical costs. There is hardly any information regarding these costs and the cost-effectiveness of collaboratives, and little knowledge about how they could be made more effective. Insight is also needed into the factors that influence the success of individual teams. There are no data regarding the sustainability of improvements.

Interventions

BEHAVIORALBreakthrough collaborative

Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care

Sponsors

Radboud University Medical Center
Lead SponsorOTHER
ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Dutch Institute for HealthCare Improvement (CBO)
CollaboratorUNKNOWN
College of Health Insurances CVZ
CollaboratorUNKNOWN

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* each patient, male or female, visiting the hospital outpatient clinic or general practice with type II diabetes mellitus during a specified period. Patients should be able to read and write the Dutch language.

Exclusion criteria

* pregnancy * patients with a life expectancy \< 1 year

Design outcomes

Primary

MeasureTime frame
HbA1cbaseline, after 12 months and after 24 months

Secondary

MeasureTime frame
To improve the patient outcomes mentioned above, teams are supported:baseline, after 12 months and after 24 months
(I) to introduce self-management of patients,baseline, after 12 months and after 24 months
(II) to change professional performance and the organisation of care (by implementing guidelines and local protocols focusing on the prevention of severe complications and introducing diabetes nurses) andbaseline, after 12 months and after 24 months
(III) to introduce a system to administrate clinical parameters.baseline, after 12 months and after 24 months
These intermediate outcomes will be measured as well, in both the intervention and the control group.baseline, after 12 months and after 24 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026